The FDA-cleared system delivers radiofrequency energy directly to the tip of a shapeable, radiopaque cannula, according to Englewood, Colorado–based Circa Scientific. The company says the design enables precise navigation and controlled crossing during procedures requiring left heart access, such as atrial fibrillation ablations, left atrial appendage occlusions, and mitral valve interventions. The zero-exchange design means clinicians can maintain guidewire accessibility throughout, enhancing procedural efficiency.
“The introduction of CrossWise represents a meaningful advancement in transseptal access,” Circa Scientific President and CEO Lee Geist said in a news release. “The system is designed to offer consistent performance while enhancing control, visibility, procedural efficiency and potential cost savings for physicians.”
Dr. Gregory Feld, of Sulpizio Cardiovascular Center at UC San Diego, had early clinical experience with the system. “CrossWise is a valuable addition to our EP lab, offering significant benefits for the many procedures requiring transseptal access. Its seamless integration with our existing tools and techniques ensures it adapts effortlessly to our established workflow,” he said.
Circa Scientific says CrossWise is the first commercial release of a new product under its CardioCentric strategy.
